Anavex Life Sciences Corporation

Research Anavex Life Sciences Corporation (AVXL) on Bullrun: market cap USD 240.95M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAVXL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 240.95M
• Financial periodFY2025
• Net income-USD 46.38M

Valuation Snapshot

latest market cap is USD 240.95M.

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease;

Frequently asked questions

What is Anavex Life Sciences Corporation's market cap?

Anavex Life Sciences Corporation's market capitalization is USD 240.95M.

What does Anavex Life Sciences Corporation do?

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS)...